The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
Open accessAbstract
Inhibition of BCL-2, MCL-1, and BCL-X L eradicates CML stem cells in a mouse model and primary blast crisis samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485 · cited 1×
“Furthermore, in these patients, leukemia stem cells can also originate from progenitor cells that acquire self-renewal capacity (10).”
BackgroundCorbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Self-citationCopland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics
Hata, A. N., Engelman, J. A., & Faber, A. C. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0011 · Cited by 619
Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347849 · Cited by 351
Research works printed but not linked: 45
- 10.1182/blood.V99.1.319 · DOI · Paper page
- 10.1182/blood-2004-08-3373 · DOI
- 10.1038/sj.leu.2403724 · DOI
- 10.1002/hon.813 · DOI
- 10.1182/blood.V94.6.2056 · DOI · Paper page
- 10.1182/blood-2013-02-483750 · DOI · Paper page
- 10.1182/blood.V99.10.3530 · DOI · Paper page
- 10.1016/j.molcel.2016.02.019 · DOI · Paper page
- 10.1182/blood-2012-07-445635 · DOI
- 10.1016/j.ccr.2006.10.006 · DOI · Paper page
- 10.1182/blood-2008-12-196055 · DOI · Paper page
- 10.1016/j.stem.2012.12.013 · DOI · Paper page
- 10.1016/j.stem.2012.12.011 · DOI · Paper page
- 10.1002/cncr.27568 · DOI
- 10.1182/blood-2004-02-0749 · DOI · Paper page
- 10.1084/jem.191.6.977 · DOI · Paper page
- 10.1038/leu.2011.285 · DOI
- Kuroda J., Kimura S., Andreeff M., Ashihara E., Kamitsuji Y., Yokota A., Kawata E., Takeuchi M., Tanaka R., Murotani Y., Matsumoto Y., Tanaka H., Strasser A., Taniwaki M., Maekawa T., ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br. J. Haematol. 140, 181–190 (2008). · DOI
- 10.1038/sj.cdd.4402168 · DOI
- 10.18632/oncotarget.5890 · DOI
- 10.1038/nm.3048 · DOI · Paper page
- 10.1182/blood-2013-01-475855 · DOI · Paper page
- 10.1038/leu.2013.377 · DOI
- 10.1038/leu.2014.1 · DOI
- 10.1038/leu.2014.72 · DOI
- 10.1158/2159-8290.CD-13-0609 · DOI · Paper page
- 10.1111/bjh.12457 · DOI
- 10.18632/oncotarget.1925 · DOI
- 10.1016/j.ccr.2010.03.011 · DOI · Paper page
- 10.1038/sj.leu.2402608 · DOI · Paper page
- 10.1007/s10495-013-0954-z · doi:10.1007/s10495-013-0954-z
- 10.1002/cncr.26679 · DOI · Paper page
- 10.1007/s00277-015-2318-y · DOI
- 10.1182/blood-2003-03-0768 · DOI
- 10.1182/blood-2003-12-4369 · DOI · Paper page
- 10.1182/blood.V124.21.118.118 · DOI
- 10.1111/cas.12849 · DOI
- 10.1016/j.cell.2013.09.018 · DOI
- 10.1016/j.ccr.2011.11.004 · DOI
- 10.1038/leu.2011.360 · doi:10.1038/leu.2011.360
- 10.1158/1535-7163.MCT-09-0386 · DOI
- Studeny M., Marini F. C., Champlin R. E., Zompetta C., Fidler I. J., Andreeff M., Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res. 62, 3603–3608 (2002).
- 10.1016/j.leukres.2013.04.018 · DOI
- 10.1002/cyto.a.22628 · DOI
- 10.1016/j.jim.2009.06.008 · DOI · Paper page
Cited by
The BCL-2 arbiters of apoptosis and their growing role as cancer targets
Adams, J. M., & Cory, S. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.161 · Cited by 530
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2018) · American Journal of Hematology · doi:10.1002/ajh.25011 · Cited by 413
Self-citationChronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
Jabbour, E., & Kantarjian, H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25792 · Cited by 410
Self-citationThe leukaemia stem cell: similarities, differences and clinical prospects in CML and AML
Vetrie, D., Helgason, G. V., & Copland, M. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0230-9 · Cited by 349
Pathways and mechanisms of venetoclax resistance
Bose, P., Gandhi, V., & Konopleva, M. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2017.1283032 · Cited by 302
Self-citation
Metadata
- Authors
- Carter, B. Z., Mak, P. Y., Mu, H., Zhou, H., Mak, D. H., Schober, W., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., Cortes, J., Kantarjian, H., Konopleva, M., & Andreeff, M.
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra117-355ra117
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2516246505
- Cited by
- 170
- References
- 6
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- NIH (P01CA49639, P30CA016672)
- Paul and Mary Haas Chair in Genetics
- AbbVie Inc.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. https://app.cochat.ai/papers/10.1126/scitranslmed.aag1180
- The paper
- Carter, B. Z., Mak, P. Y., Mu, H., Zhou, H., Mak, D. H., Schober, W., Leverson, J. D., Zhang, B., Bhatia, R., Huang, X., Cortes, J., Kantarjian, H., Konopleva, M., & Andreeff, M. (2016). Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aag1180
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.